Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Construction in Progress (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Construction in Progress for 11 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Construction in Progress fell 34.62% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Dec 2025, down 34.62%, and an annual FY2025 reading of $1.7 million, down 34.62% over the prior year.
  • Construction in Progress was $1.7 million for Q4 2025 at Heron Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $15.9 million in Q4 2021 and bottomed at $1.7 million in Q4 2025.
  • Average Construction in Progress over 5 years is $6.4 million, with a median of $5.4 million recorded in 2022.
  • The sharpest move saw Construction in Progress tumbled 66.04% in 2022, then increased 16.67% in 2023.
  • Year by year, Construction in Progress stood at $15.9 million in 2021, then crashed by 66.04% to $5.4 million in 2022, then increased by 16.67% to $6.3 million in 2023, then plummeted by 58.73% to $2.6 million in 2024, then plummeted by 34.62% to $1.7 million in 2025.
  • Business Quant data shows Construction in Progress for HRTX at $1.7 million in Q4 2025, $2.6 million in Q4 2024, and $6.3 million in Q4 2023.